Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT01977482

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01977482
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Japan, Norway, Poland, Russia, South Korea, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01977482. Randomized; triple masking; primary purpose treatment. Start 2013-11-01 (registry gives no type); primary completion 2015-02-01 (actual). Results posted on 2017-02-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
Condition
Anaemia
Intervention (Drug)
GSK1278863
Intervention (Drug)
Placebo
Intervention (Drug)
rhEPO
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01977482
Content hash
5337a0f4c23700bdde82139adccc06162acfb9921037f710a47ef45dccd1886f